可溶性介质与临床特征可识别SLE患者亲属的疾病转化风险
本研究随访409例基线不符合4条ACR分类标准的SLE患者血亲,平均6.4年随访中45例(11%)转化为分类SLE。转化者基线自身抗体特异性更多、SLE-CSQ评分更高,且血浆B淋巴细胞刺激因子、干细胞因子及干扰素相关趋化因子升高,TGFβ和IL-10降低。GEE分析显示基线SLE-CSQ评分或ACR评分及SCF、TGFβ水平(而非自身抗体)是SLE转化的独立预测因素。
要点
- SLE患者未患病血亲6.4年随访中11%转化为分类SLE。
- 基线SLE-CSQ评分或ACR评分及血浆SCF、TGFβ水平可独立预测转化。
- 自身抗体虽与转化相关,但多因素分析中非独立预测因素。
核心结论
- 临床前可溶性介质水平变化可能预测SLE患者亲属向分类疾病的转化。
研究设计与样本
- 随访研究纳入409例基线不符合4条ACR分类标准的SLE患者血亲,检测血清和血浆自身抗体及52种可溶性介质,采用广义估计方程(GEE)分析预测因素。
主要发现
- 409例未患病亲属中45例(11%)在随访时转化为分类SLE,平均随访时间6.4年。
- 转化者基线 lupus相关自身抗体特异性更多且SLE-CSQ评分更高(P < 0.0001)。
- 转化者基线血浆B淋巴细胞刺激因子、干细胞因子(SCF)及干扰素相关趋化因子升高(P ≤ 0.02),同时调节介质TGFβ和IL-10降低(P ≤ 0.03)。
- GEE分析显示基线SLE-CSQ评分或ACR评分及血浆SCF和TGFβ水平是SLE转化的显著独立预测因素(P ≤ 0.03),而自身抗体非独立预测因素。
关键数值与推荐
- 基线不符合4条ACR分类标准;随访中转化为分类SLE定义为达到分类标准。
- 转化者与未转化者比较:自身抗体特异性和SLE-CSQ评分P < 0.0001;炎症介质P ≤ 0.02;调节介质P ≤ 0.03。
- GEE分析中SLE-CSQ评分或ACR评分及SCF、TGFβ水平P ≤ 0.03。
临床怎么用
- 对SLE患者血亲可评估SLE-CSQ评分、ACR criteria数目及血浆SCF、TGFβ水平以识别高转化风险者。
- 高风险亲属可转诊风湿免疫科并考虑纳入预防试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Systemic lupus erythematosus (SLE) and other autoimmune diseases cause significant morbidity. Identifying populations at risk of developing SLE is essential for curtailing irreversible inflammatory damage. The aim of this study was to identify factors associated with transition to classified disease that would inform our understanding of the risk of SLE. METHODS: Previously identified blood relatives of patients with SLE, who had <4 American College of Rheumatology (ACR) classification criteria for SLE at baseline, were enrolled in this follow-up study (n = 409 unaffected relatives). Participants provided detailed family, demographic, and clinical information, including the SLE-specific portion of the Connective Tissue Disease Screening Questionnaire (SLE-CSQ). Serum and plasma samples were tested for the presence of lupus-associated autoantibodies and 52 soluble mediators. Generalized estimating equations (GEEs) were applied to identify factors predictive of disease transition. RESULTS: Of the 409 unaffected relatives of SLE patients, 45 (11%) had transitioned to classified SLE at follow-up (mean time to follow-up 6.4 years). Relatives who transitioned to SLE displayed more lupus-associated autoantibody specificities and higher SLE-CSQ scores (P < 0.0001) at baseline than did relatives who did not transition. Importantly, those who had developed SLE during the follow-up period also had elevated baseline plasma levels of inflammatory mediators, including B lymphocyte stimulator, stem cell factor (SCF), and interferon-associated chemokines (P ≤ 0.02), with concurrent decreases in the levels of regulatory mediators, transforming growth factor β (TGFβ), and interleukin-10 (P ≤ 0.03). GEE analyses revealed that baseline SLE-CSQ scores or ACR scores (number of ACR criteria satisfied) and plasma levels of SCF and TGFβ, but not autoantibodies, were significant and independent predictors of SLE transition (P ≤ 0.03). CONCLUSION: Preclinical alterations in levels of soluble mediators may predict transition to classified disease in relatives of SLE patients. Thus, immune perturbations precede SLE classification and can help identify high-risk relatives for rheumatology referral and potential enrollment in prevention trials.
引用
- Munroe ME, Young KA, Kamen DL, et al. Discerning Risk of Disease Transition in Relatives of Systemic Lupus Erythematosus Patients Utilizing Soluble Mediators and Clinical Features. Arthritis Rheumatol. 2017. PMID: 27863174. doi:10.1002/art.40004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。